May 3, 2018 / 5:09 AM / 3 months ago

BRIEF-Biotest: New Data From Monoclonal Antibody-Drug-Conjugate BT-062

May 3 (Reuters) - Biotest AG:

* DGAP-NEWS: BIOTEST AG: NEW DATA FROM BIOTEST’S MONOCLONAL ANTIBODY-DRUG-CONJUGATE (ADC) BT-062 IN THE THERAPY OF SOLID TUMORS

* GOOD TOLERABILITY AND SIGNS OF EFFICACY IN PHASE I/IIA CLINICAL STUDY

* VERY GOOD EFFECTIVENESS WHEN COMBINED WITH CHEMOTHERAPEUTIC AGENT IN PRECLINICAL STUDIES ON DIFFICULT TO TREAT BREAST CANCER

* BIOTEST IS SEEKING INVESTORS FOR FURTHER DEVELOPMENT OF BT-062 Source text for Eikon: Further company coverage: (Gdynia Newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below